Synedgen, Inc. has raised $1.8M in total funding.
Synedgen, Inc. is headquartered in Claremont, CA.
Gastrointestinal mucosal injury leads to unchecked inflammation and tissue damage.
Synedgen develops first-in-class, orally delivered therapeutics — led by MIIST305 — that restore mucosal barrier function to repair GI injury.
The company points to targeted therapies, scalable GMP production, excellent safety profiles, and a strong IP position as what sets its regenerative therapeutics platform apart.
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 27, 2026.